Literature DB >> 36118184

Identification of Gefitinib Resistance-Related lncRNA-miRNA-mRNA Regulatory Networks and Corresponding Prognostic Signature in Patients with Lung Adenocarcinoma.

Taoli Wang1, Zhulin Wu1, Shiguang Li1, Zhong Chen1, Yiqi Chen1, Zhenjiang Yang1.   

Abstract

Purpose: To identify and characterize gefitinib resistance-related (GefR-related) lncRNAs and construct a prediction model for lung adenocarcinoma (LUAD).
Methods: Differential expression analysis between PC9 and gefitinib-resistant PC9 (PC9GR) cell samples was performed to screen GefR-related lncRNAs and mRNAs based on the GSE34228 dataset. These lncRNAs, mRNAs, and their corresponding microRNAs (miRNAs) were used to construct the GefR-related network and PPI networks. Functional enrichment analyses were conducted using the STRING database. A prognostic signature was developed using the TCGA dataset. The reliability of the signature was tested using the Kaplan-Meier method and ROC curve. Lastly, the FZD4-associated ceRNA subnetwork was selected to confirm the in vitro expressions of the GefR-related lncRNAs using RT-qPCR assay.
Results: A GefR-related ceRNA network that consists of 35 miRNAs, 26 lncRNAs, and 179 mRNAs was constructed. Then, 20 hub genes were screened from the targeted mRNAs of the constructed PPI network, and enrichment analysis identified relevant enriched pathways. We also constructed a prognostic signature for LUAD based on nine mRNAs in the GefR-related ceRNA network. The 9-mRNA signature was an independent predictor of LUAD, the AUC produced by ROC analysis showed a good predictive power of the model, and Kaplan-Meier analysis showed poorer outcomes in the high-risk group, relative to the low-risk group. Lastly, MIR137HG and ZNF295-AS1 levels were found to be associated with gefitinib resistance and exerted their functions through the ceRNA mechanism.
Conclusion: We established a prognostic signature and identified two lncRNAs (MIR137HG and ZNF295-AS1) with potential significant roles in gefitinib resistance.
© 2022 Wang et al.

Entities:  

Keywords:  EGFR TKIs; NSCLC; ceRNA; lncRNA; lung adenocarcinoma; prognostic signature

Year:  2022        PMID: 36118184      PMCID: PMC9477152          DOI: 10.2147/IJGM.S369718

Source DB:  PubMed          Journal:  Int J Gen Med        ISSN: 1178-7074


  33 in total

Review 1.  The biology and management of non-small cell lung cancer.

Authors:  Roy S Herbst; Daniel Morgensztern; Chris Boshoff
Journal:  Nature       Date:  2018-01-24       Impact factor: 49.962

2.  The landscape of long noncoding RNAs in the human transcriptome.

Authors:  Matthew K Iyer; Yashar S Niknafs; Rohit Malik; Udit Singhal; Anirban Sahu; Yasuyuki Hosono; Terrence R Barrette; John R Prensner; Joseph R Evans; Shuang Zhao; Anton Poliakov; Xuhong Cao; Saravana M Dhanasekaran; Yi-Mi Wu; Dan R Robinson; David G Beer; Felix Y Feng; Hariharan K Iyer; Arul M Chinnaiyan
Journal:  Nat Genet       Date:  2015-01-19       Impact factor: 38.330

3.  Targeting histone deacetylase enhances the therapeutic effect of Erastin-induced ferroptosis in EGFR-activating mutant lung adenocarcinoma.

Authors:  Tuo Zhang; Beibei Sun; Chenxi Zhong; Ke Xu; Zhexin Wang; Paul Hofman; Tatsuya Nagano; Antoine Legras; Daniel Breadner; Biagio Ricciuti; Duilio Divisi; Ralph A Schmid; Ren-Wang Peng; Haitang Yang; Feng Yao
Journal:  Transl Lung Cancer Res       Date:  2021-04

4.  An Anti-EGFR/anti- HER2 Bispecific Antibody with Enhanced Antitumor Activity Against Acquired Gefitinib-Resistant NSCLC Cells.

Authors:  Yan Si; Xinxin Pei; Xiangfang Wang; Qianqian Han; Changzhi Xu; Buchang Zhang
Journal:  Protein Pept Lett       Date:  2021       Impact factor: 1.890

5.  Weak seed-pairing stability and high target-site abundance decrease the proficiency of lsy-6 and other microRNAs.

Authors:  David M Garcia; Daehyun Baek; Chanseok Shin; George W Bell; Andrew Grimson; David P Bartel
Journal:  Nat Struct Mol Biol       Date:  2011-09-11       Impact factor: 15.369

6.  Sensitivity of non-small cell lung cancer to erlotinib is regulated by the Notch/miR-223/FBXW7 pathway.

Authors:  Haiwei Zhang; Fanglin Chen; Yongpeng He; Lin Yi; Chuang Ge; Xiaolong Shi; Chao Tang; Donglin Wang; Yongzhong Wu; Weiqi Nian
Journal:  Biosci Rep       Date:  2017-06-21       Impact factor: 3.840

7.  miRTarBase 2020: updates to the experimentally validated microRNA-target interaction database.

Authors:  Hsi-Yuan Huang; Yang-Chi-Dung Lin; Jing Li; Kai-Yao Huang; Sirjana Shrestha; Hsiao-Chin Hong; Yun Tang; Yi-Gang Chen; Chen-Nan Jin; Yuan Yu; Jia-Tong Xu; Yue-Ming Li; Xiao-Xuan Cai; Zhen-Yu Zhou; Xiao-Hang Chen; Yuan-Yuan Pei; Liang Hu; Jin-Jiang Su; Shi-Dong Cui; Fei Wang; Yue-Yang Xie; Si-Yuan Ding; Meng-Fan Luo; Chih-Hung Chou; Nai-Wen Chang; Kai-Wen Chen; Yu-Hsiang Cheng; Xin-Hong Wan; Wen-Lian Hsu; Tzong-Yi Lee; Feng-Xiang Wei; Hsien-Da Huang
Journal:  Nucleic Acids Res       Date:  2020-01-08       Impact factor: 16.971

8.  Analysis of lncRNA, miRNA and mRNA-associated ceRNA networks and identification of potential drug targets for drug-resistant non-small cell lung cancer.

Authors:  Xiangzhen Kong; Shousen Hu; Yongliang Yuan; Yue Du; Zijia Zhu; Zhizhen Song; Shanshan Lu; Chang Zhao; Dan Yan
Journal:  J Cancer       Date:  2020-03-05       Impact factor: 4.207

9.  Identification of Hub Genes and Small Molecule Drugs Associated with Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer.

Authors:  Guangda Li; Yunfei Ma; Mingwei Yu; Xiaoxiao Li; Xinjie Chen; Yu Gao; Peiyu Cheng; Ganlin Zhang; Xiaomin Wang
Journal:  J Cancer       Date:  2021-07-02       Impact factor: 4.207

10.  Bioinformatics analysis for the identification of key genes and long non-coding RNAs related to bone metastasis in breast cancer.

Authors:  Xu Teng; Tianshu Yang; Wei Huang; Weishi Li; Lin Zhou; Zihang Wang; Yajuan Feng; Jingyao Zhang; Xin Yin; Pei Wang; Gen Li; Hefeng Yu; Zhongqiang Chen; Dongwei Fan
Journal:  Aging (Albany NY)       Date:  2021-07-05       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.